Alentis Therapeutics AG
Company Overview
Management
Markus Meyer
Neuenburg, DE
Manager
Joint signing authority (any two to sign)
Valentina Aureggi
Zürich
Joint signing authority (any two to sign)
Geoffrey Teixeira
Basel
Joint signing authority (any two to sign)
Alberto Toso
Basel
Joint signing authority (any two to sign)
Naveed Siddiqi
London, GB
Member of the board
Joint signing authority (any two to sign)
Luigi Manenti
Livingston, US
Joint signing authority (any two to sign)
Rafaele Tordjman épouse Baruchel
Paris, FR
Member of the board
Joint signing authority (any two to sign)
Cyril Barthelemy
Le Castera, FR
Joint signing authority (any two to sign)
William Pao
Nashville, US
Member of the board
Joint signing authority (any two to sign)
Luca Santarelli
Basel
Chairperson of the board
Joint signing authority (any two to sign)
Dina Chaya Moghrabi
London, GB
Member of the board
Joint signing authority (any two to sign)
Anna Chen
San Diego, US
Member of the board
Joint signing authority (any two to sign)
Sandipkumar Kapadia
Princeton, US
Member of the board
Joint signing authority (any two to sign)
Brian Liu
Mountain View, US
Member of the board
Joint signing authority (any two to sign)
Jonathan Freve
Northborough, US
Joint signing authority (any two to sign)
Roberto Iacone
Basel
Member of the board
Joint signing authority (any two to sign)
Aditya Venugopal
Castile, US
Joint signing authority (any two to sign)
Seokho Yoon
Tenafly, US
Joint signing authority (any two to sign)
Building smart people network graph...
Fetching people and their companies
Address & Locations
Primary Address
Loading map...
| No. | Journal No. | Journal date | SOGC | SOGC date | Page / ID |
|---|---|---|---|---|---|
| 1 | (Transfer seat) | (Transfer seat) | |||
| 2 | 5689 | 10.10.2025 | 199 | 15.10.2025 | 1006458817 |
| 3 | 5576 | 06.10.2025 | 194 | 08.10.2025 | 1006452922 |
| 4 | 5241 | 19.09.2025 | 184 | 24.09.2025 | 1006441014 |
| 5 | 4990 | 05.09.2025 | 174 | 10.09.2025 | 1006429636 |
| 6 | 3336 | 16.06.2025 | 116 | 19.06.2025 | 1006360776 |
| 7 | 1061 | 18.02.2025 | 36 | 21.02.2025 | 1006263970 |
| 8 | 6473 | 19.11.2024 | 228 | 22.11.2024 | 1006185663 |
| 9 | 5837 | 18.10.2024 | 206 | 23.10.2024 | 1006160996 |
| 10 | 2464 | 26.04.2024 | 84 | 01.05.2024 | 1006022553 |
Company Purpose
Die Gesellschaft bezweckt die Entwicklung und Kommerzialisierung von Therapeutika auf dem Gebiet der Humanmedizin, insbesondere zur Behandlung von chronischen Erkrankungen und Krebs. Die Gesellschaft kann sich daneben an anderen Unternehmen irgendwelcher Art im In- und Ausland beteiligen, solche gründen, übernehmen und mit ihnen fusionieren. Sie kann Liegenschaften und Immaterialgüterrechte im In- und Ausland erwerben, belasten und veräussern sowie durch Beschluss des Verwaltungsrates Zweigniederlassungen und Agenturen im In- oder Ausland errichten.